Director Maeve O'Meara resigns effective Jan 1, 2025; Gabriel Ling to become independent director

Oncology Institute, Inc.

Maeve O'Meara notified board of her resignation as director for personal reasons, effective January 1, 2025.
Resignation is not the result of any disagreement with the company, board, or operations.
Board determined that existing director Gabriel Ling will qualify as independent as of the Effective Date.
After the departure, a majority of independent directors will remain on the board.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Maeve O'Meara

Director

TOI · Oncology Institute, Inc.

Effective: 2025-01-01
Filed: November 12, 2024, 6:59 PM ET

On November 8, 2024, Maeve O’Meara notified the Board of Directors of The Oncology Institute, Inc. (the “Company”) of her intention to resign as a director of the Company for personal reasons, effective as of January 1, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Maeve O'Meara resigned as Director at Oncology Institute, Inc..

Action: resigned
Role: Director

Exact text from the filing

On November 8, 2024, Maeve O’Meara notified the Board of Directors of The Oncology Institute, Inc. (the “Company”) of her intention to resign as a director of the Company for personal reasons, effective as of January 1, 2025 (the “Effective Date”).

View on SEC.gov

Oncology Institute, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-24-001491

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.